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1 
During a viral infection, when the virus enters into the cytoplasm, dif-
ferent cell types are able to produce interferons (IFN) as a result of 
interaction between intracellular pattern recognition receptors (PRR) 
and RNA helicases. This interferon activates and establishes an anti-
viral state which limits further spread of the virus. Morbilliviruses are 
highly infectious viruses that spread mainly via direct contact. The ge-
nome of morbillivirus contains six genes, translated into eight proteins. 
The morbillivirus P gene is translated, in addition to the P protein, to V 
and C proteins. These proteins are directly related to inhibiting type I 
interferon expression and signalling and thus limit transcription of in-
terferon-stimulated genes (ISGs). Previous studies show that V and C 
proteins of morbilliviruses have an ability to interfere with the type I 
IFN pathway at different levels, and the V protein is the main inhibitor. 
This study focuses on the immunomodulatory capability of a newly dis-
covered Feline morbillivirus (FmoPV) in comparison with the well-
known Canine distemper morbillivirus (CDV) of dogs and Measles 
morbillivirus (MeV) of humans. The V proteins of all the tested viruses 
strongly inhibited the type I IFN pathway compared to the C proteins. 
The V and C proteins of FmoPV showed lower immunomodulatory ca-
pabilities compared to CDV and MeV. The V protein of CDV showed 
highest inhibitory ability of tested V proteins and the C protein of the 
MeV showed the highest inhibitory ability of the tested C proteins. In 
both cases, significant inhibitory similarities between V and C protein 
of CDV and MeV were observed.  
  
Keywords: Feline morbillivirus, Canine distemper morbillivirus, Mea-
sles morbillivirus, Type I Interferon, C protein, V protein. 
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The virus genus known as morbillivirus is highly contagious and 
spread mostly by direct contact. To date seven species of morbilli-
viruses have been identified. The most known among them is the Mea-
sles morbillivirus (MeV), which causes a disease commonly known as 
measles. Measles is one of the main causes of child mortality around 
the world. However, a successful vaccination program against the vi-
rus reduced the measles deaths by 84% during the years 2000-2016. 
Rinderpest morbillivirus (RPV), which infects cattle, is the second virus 
eradicated in the world by successful vaccination programs. This virus 
has, pathogenically, a very close relationship with MeV. The Canine 
distemper morbillivirus (CDV) causes infections in dogs and other car-
nivores species and it is closely related to Phocine distemper morbilli-
virus (PDV), which causes distemper disease in seals. Small ruminant 
morbillivirus (SRMV) and Cetacean morbillivirus (CeMV) are another 
two morbilliviruses that cause disease in small ruminants and disease 
in dolphins and whales, respectively. The Feline morbillivirus 
(FmoPV), which causes infections in cats, is the latest identified mor-
billivirus species among all the seven morbilliviruses.   
 
The morbillivirus genome consists of six genes, namely N, P, M, F, H 
and L, which encode eight proteins. Interestingly, the P gene encodes 
two extra proteins, namely V and C protein, in addition to the P protein. 
These V and C proteins are very important for morbillivirus to fight 
against the host immune system. These proteins have an ability to in-
hibit the signalling protein interferon (IFN), which activates the antivi-
rus defence and is produced by the host cells.  
 
This study examined the ability of the V and C proteins of the morbilli-
viruses FmoPV, CDV and MeV to inhibit IFN and specifically type I 
IFN. To fulfil this goal, the poly(I:C) stimulated human embryonic kid-
ney (HEK) cells, which mimicked as virus infected cells were trans-
fected with V and C protein plasmids of FmoPV, CDV and MeV. 
Poly(I:C) is a synthetic double-stranded RNA molecule that mimics a 
molecular pattern associated with virus infections and activates type I 
IFN responses. The V and C proteins of FmoPV, CDV and MeV were 
produced in HEK cells. The ability of these proteins to inhibit type I IFN 
Summary 
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levels were measured using reporter system. According to the results, 
the V proteins of all the tested viruses strongly inhibit type I IFN sig-
nalling in contrast to the C proteins. The V and C proteins of FmoPV 
showed weaker inhibitory capabilities as compared to the correspond-
ing proteins of CDV and MeV. The V protein of CDV showed the high-
est inhibitory ability of all the tested V proteins and the C protein of the 
MeV showed the highest ability of all the tested C proteins. This study 
and its results are helpful for future research regarding morbilliviruses, 
particularly FmoPV, and vaccine development studies.   
 
Keywords: Feline morbillivirus, Canine distemper morbillivirus, Mea-
sles morbillivirus, Type I Interferon, C protein, V protein.   
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Morbilliviruses belong to the family Paramyxoviridae and the order of 
Mononegavirales. They are highly infectious and spread mostly by direct 
contact (Pfeffermann et al., 2018). They are responsible for several severe 
and moderate distinct diseases, which usually cause long-lasting immuno-
suppression in humans and animals. There are seven species of morbilli-
viruses identified until today, namely Canine distemper morbillivirus (CDV), 
Measles morbillivirus (MeV), Small ruminant morbillivirus (SRMV), Cetacean 
morbillivirus (CeMV), Phocine distemper morbillivirus (PDV), Rinderpest 
morbillivirus (RPV) and the recently discovered Feline morbillivirus (FmoPV) 
(de Vries et al., 2015).  
1.1 Structure  
 
All the morbilliviruses share the same structural setup. Virions have 
diameters of about 150 nm and are pleomorphic (Pfeffermann et al., 2018). 
Morbilliviruses have a non-segmented, negative-sense single-stranded lin-
ear RNA genome that contains six genes in the order 3′-N-P/V/C-M-F-H-L-
5′ and a set of eight encoded proteins (Figure 1). The lipid envelope of the 
morbilliviruses contains three viral proteins named Matrix protein (M), Fusion 
protein (F) and Hemagglutinin (H) (Figure 2). Nucleocapsid protein (N), 
Phosphoprotein (P) and Polymerase protein (L) (da Fontoura Budaszewski 
and von Messling, 2016) are the three proteins contained in the ribonuclease 
protein complex. In addition to P protein, the P gene also encodes two pro-
teins namely V and C proteins (Figure 1). The P protein is a direct mRNA 
translation of the P gene, while the C protein is generated by initiation of 
translation at the second AUG of an internal open reading frame (ORF) of 
the P gene transcripts. Interestingly, the V protein is produced by inserting 
1 Introduction 
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a guanidine (G) residue into the mRNA transcript resulting in a switching of 
the reading frame in the coding sequence (de Vries et al., 2015; Sanz 
Bernardo et al., 2017). This is called mRNA editing.  
 
 
Figure 1. Negative-sense single-stranded linear RNA genome of morbilliviruses. 
Adapted from Swiss Institute of Bioinformatics (2018). 
 
 
 
Figure 2. Structure of a morbillivirus. Adapted from Swiss Institute of Bioinformatics 
(2018). 
1.2 Feline morbillivirus (FmoPV) 
 
FmoPV is mainly infecting domestic cats. It was first identified in 2012 
in China, Hong Kong and Japan (Woo et al., 2012). Later the same virus 
was identified from various other places around the world, including Sweden 
(Dahl, 2018). Phylogenetically FmoPV is related to the other morbilliviruses, 
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but pathogenically it differs from the others (de Vries et al., 2015). For ex-
ample, FmoPV has been suggested to be associated with chronic renal fail-
ure and tubulointerstitial nephritis which is a disease common in aged cats. 
However, the other morbilliviruses have not been shown to be associated 
with tubulointerstitial nephritis. In contrast to the other morbillivirus species, 
FmoPV is thus mostly associated with problems in the urinary system (Sharp 
et al., 2016).  
1.3 Measles virus (MeV) 
 
Measles has been known for a very long time. MeV is one of the most 
common morbilliviruses, and infections result in significant levels of morbid-
ity and mortality when humans are infected at an early age. The symptoms 
of the disease are fever, cough, skin rash and conjunctivitis (de Vries et al., 
2015). This disease also causes immune suppression. Severe cases of 
measles lead to lethal conditions such as gastrointestinal diseases and 
pneumonia. MeV is different from other morbilliviruses due to the fact that 
its host range is limited to humans and non-human primates. Therefore, a 
very successful vaccine has been developed against MeV. However, a min-
imum of 95% herd immunity is needed to prevent outbreaks of this virus 
(Fox, 1983). So, even today measles cases are sometimes appearing be-
cause some people choose to opt out from being vaccinated due to eco-
nomic, cultural and political beliefs.  
1.4 Canine distemper virus (CDV)  
 
The canine distemper disease has been known since the 17th century. 
It is a disease affecting dogs and a broad range of other carnivorous animals 
causing a very high rate of morbidity and mortality. Due to the severity of the 
disease, most domestic carnivores are vaccinated against this virus (de 
Vries et al., 2015). The CDV infection impacts the gastrointestinal, respira-
tory and central nervous systems very seriously. The symptoms of the dis-
ease vary based on the age, immune state of the animal and strain of the 
virus (Beineke et al., 2015).  
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1.5 Virus infections and interferon (IFN) responses  
 
When an infection from a virus occurs, the host innate immune re-
sponses are activated by the recognition of viral pathogen-associated mo-
lecular patterns (PAMPs) via cellular pattern recognition receptors (PRRs) 
(González-Navajas et al., 2012). This recognition activates the intracellular 
signalling pathway that leads to the production of interferons (IFNs) one of 
a number of pro-inflammatory cytokines. A virus-resistant state in cells is 
later induced by IFN α/β. Also, these are highly important for later adaptive 
immunity responses.  
 
 
 
Figure 3. Virus infections and type I IFN responses. Adapted from González-Nava-
jas et al. (2012). 
As shown in Figure 3, the IFN α/β bind to the interferon-α receptor 
that is composed of two subunits, interferon alpha receptor subunit 1 and 2 
(IFNAR1/IFNAR2) (Pfeffermann et al., 2018). This binding activates two 
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members of this pathway, Janus kinase 1 (JAK1) and tyrosine kinase 2 
(TYK2) (Pfeffermann et al., 2018).  As a result of the phosphorylation by 
these two kinases, signal transducer and activator of transcription (STAT) 
proteins are recruited to the pathway. There are three different STAT pro-
teins (STAT1, STAT2 and STAT3) that are of importance in viral infections. 
STAT1 and STAT2 proteins are subjected to phosphorylation and form a 
heterodimer complex, together with interferon regulatory factor 9 (IRF-9), a 
DNA binding protein (González-Navajas et al., 2012). This heterodimer com-
plex is known as interferon stimulated gene factor 3 (ISGF3). Thereafter, 
ISGF3 translocates to the nucleus from the cytoplasm and binds to inter-
feron stimulated genes (ISGs). The binding site is located in the promoter 
region of the ISG gene, a specific conserved nucleotide sequence of about 
15 bp size known as interferon stimulated response element (ISRE) (Chin-
nakannan et al., 2013). Activation of ISG gene transcription induces the ex-
pression of a large number of proteins and ultimately leads to an antiviral 
state of the cell. 
1.6 Strategies of type I IFN inhibition of paramyxoviruses  
 
In general viruses of the family of Paramyxoviridae use different strat-
egies to inhibit the type I IFN pathway. The results obtained from previous 
studies show that the majority of the viruses from the genera Rubulavirus 
and Avulavirus use the strategy of degradation of STAT proteins for their 
immunomodulation (Chinnakannan et al., 2013). On the other hand, viruses 
of the genera Morbillivirus, Henipavirus and Respirovirus are not involved in 
degradation of STAT proteins, and instead these viruses inhibit the phos-
phorylation of STAT proteins or nuclear accumulation. Even the immuno-
modulatory capability of the V and C proteins differ between genera. The V 
protein of viruses of the genera Henipavirus and Morbillivirus blocks IFN sig-
nalling, while the C protein of respiroviruses blocks IFN signalling. (Chinna-
kannan et al., 2013). 
1.7 Morbillivirus V and C proteins 
 
The V and C protein of morbilliviruses, known as non-structural or 
alternative proteins, are encoded by the above-mentioned P gene. The V 
protein is larger than the C protein for every species of morbillivirus. Even 
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the V proteins have more versatile immunomodulatory characteristics than 
the C protein. The V and C proteins of morbilliviruses also play a major role 
in transcription and translation during the viral life cycle (Su et al., 2015). 
The evasion of the interferon response by the V protein of morbilliviruses is 
mediated by the V-specific domains consisting of a highly conserved motif 
that contains seven cysteine residues (Fontana et al., 2008). Different mor-
billiviruses use different blocking mechanisms to inhibit the type I and type 
II interferon pathways (Chinnakannan et al., 2013). The V protein of all mor-
billiviruses can interfere with STAT and STAT2 components of the host's 
IFN response pathway (Svitek et al., 2014) and the result of this will lead to 
the inhibition of the STAT nuclear translocation (Horvath, 2004). Further-
more, previous studies have shown that if the V and C proteins are defective 
MeV replication is reduced and those MeV viruses have a shorter life span 
compared to the wild type (Devaux et al., 2008). In the IFN pathways, the V 
proteins of morbilliviruses form a complex with TYK2 and JAK1. The newly 
formed complex has the ability to inhibit phosphorylation of STAT1 and 
STAT2 (Chinnakannan et al., 2013).  
 
The C protein studies are mostly related to different wild type and 
vaccine strains of MeV. Previous studies have shown that the C protein has 
the ability to downregulate viral polymerase activity. Also, it increases the 
production of the C protein of MeV and reduces the IFNα/β production of 
infected cells. Further, it also enhances the viral activity that inhibits IFNα/β 
signalling (Shaffer et al., 2003). For viruses that lack or have defective C 
protein, viral RNA synthesis results in highly stimulated IFN production 
(Nakatsu et al., 2008). Further studies have also shown that C protein of 
MeV binds to STAT1 and inhibits the phosphorylated dimerization activity of 
the pathway (Yokota et al., 2011).  
1.8 V and C proteins of FmoPV  
 
The V and C proteins of the newly discovered FmoPV are apparently 
different from those of other morbilliviruses. FmoPV has the largest genome 
size, 16050 nt, of all the morbilliviruses (CDV consists of 15690 nt and MeV 
consists of 15894 nt). Even the amino acid length of the V and C proteins of 
FmoPV, 276 and 170 respectively, is different from the V and C proteins of 
CDV, 299 and 174, respectively, and MeV, 299 and 186, respectively (Fig-
ures 4 and 5).  
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Therefore, it is interesting to investigate the immunomodulatory ca-
pabilities of the V and C proteins of FmoPV in comparison to these other 
viruses. Such a comparison has not previously been conducted, specifically 
a systematic comparison between FmoPV, CDV and MeV.  
1.9 The main goal of study 
 
The main goal of this thesis was to investigate the ability of V and C 
proteins of FmoPV to inhibit induction of immune response by type I inter-
feron and compare it to other related morbilliviruses such as MeV and CDV.  
16 
 
 
The thesis aims at understanding how the type I IFN inhibition of V 
and C proteins of FmoPV differ from that of V and C proteins of CDV and 
MeV. In doing so, several methods in bioinformatics, cloning of viral genes, 
transfection of proteins and measuring type I IFN levels using reporter sys-
tem were being used. Several protocols available at the manufacture’s 
Thermo Fisher, Mirus, Promega and Tecan were used for these experi-
ments.  
 
Bioinformatics methods were used, as described below, for obtaining 
the cDNA sequences of V and C proteins from whole genomes. This was 
followed by multiple sequence alignment analysis of proteins of FmoPV, 
CDV and MeV (Figures 4 and 5). Cloning methods were used for the ex-
pression of viral genes. The relative immunomodulatory capabilities of the V 
and C proteins of FmoPV, CDV and MeV in inhibiting type I IFN signalling 
were measured by a modified dual luciferase assay reporter system using 
the expression of an ISRE-responsive reporter plasmid. The detailed exper-
imental setup is shown below. 
2.1 Construction of V and C expression plasmid from 
FmoPV, CDV and MeV  
 
The V and C plasmid vectors (pCMV-3Tag-1a) of FmoPV, CDV and 
MeV were constructed at GenScript Inc (Appendix 1). The sequences used 
for de novo gene synthesis of C and V from full genome sequences were 
available at National Center for Biotechnology Information (NCBI) GenBank: 
FmoPV strain US1, complete genome – Accession number: KR014147; 
2 Methods 
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CDV isolate CDV2784/2013, complete genome Accession number: 
KF914669.1; MeV isolate 97-45881, complete genome – Accession num-
ber: DQ227319.1. FmoPV (V and C; cDNAs): For the expression of the C 
protein, the P gene was used (nt 1812 - 2324 of the genome sequence), 
while for the V protein the same gene was used, but with the addition of an 
extra G at nt position 2460 and a different length of the gene (nt 1781 – 
2610).  As restriction sites, EcoRI at the 5’ end and HindIII at the 3’ end were 
added for both cDNAs (Appendix 1 - Figure 1). CDV (V and C; cDNAs): For 
the expression of the C protein, the P gene was used (nt 1823 -2347 of the 
genome sequence), while for the V protein the same gene was used, but 
with the addition of an extra G at nt position 2493 and a different length of 
the gene (nt 1801– 2699). The restriction sites EcoRI at the 5’end and HindIII 
at the 3’ end were added for both cDNAs (Appendix 1 - Figure 2). MeV (V 
and C; cDNAs): For the expression of the C protein, the P gene was used 
(nt 1829 -2389 of the genome sequence), while for the V protein the same 
gene was used, but with the addition of an extra G at nt position 2498 and a 
different length of the gene (nt 1781 – 2610). As restriction sites, BamHI at 
the 5’end and EcoRI at the 3’end were added for both cDNAs (Appendix 1 - 
Figure 3). 
 
2.2 Analysis of V and C genes and proteins of FmoPV, 
CDV and MeV 
 
The V and C proteins of FmoPV, CDV and MeV were analysed using 
the Clustal O multiple sequence alignment tool. The sequences of each V 
and C protein were obtained from the NCBI GenBank sequences of FmoPV, 
CDV and MeV described in section 2.1.  
 
2.3 Transformation of vector plasmids 
 
The vector plasmids were transformed into Sub-cloning Efficiency™ 
DH5α™ Competent Cells (Invitrogen Inc.) according to the manufacturer’s 
protocol. A 30 l aliquot of Escherichia coli DH5α cells and 1 l (1 ng) of the 
V or C plasmids were used. The plasmid solution and E. coli DH5α cells 
were thawed on ice. Then 1 l (1 ng)  of plasmid solution was added to the 
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cells followed by 30 minutes of incubation on ice. The tubes were heat 
shocked at 42°C for 20 seconds and placed on ice for 2 minutes. The cells 
with plasmids were added to 500 l of pre-warmed Luria Broth (LB) media 
tubes and incubated at 37°C for 1 hour with shaking (225 rpm). After incu-
bation, 20 l to 100 l of the transformed cells was spread on pre-warmed 
agar plates containing 50 µg/ml kanamycin. The plates were incubated over-
night at 37°C. Next day, a single colony was picked from the agar plate and 
transferred to 1.5 ml of LB medium with kanamycin and the bacterial culture 
was incubated at 37°C for 8 hours at with shaking (225 rpm). An aliquot of 
100 l was inoculated to a flask  containing 200 ml of LB growth medium 
with 50 µg/ml kanamycin. The flasks were incubated at 37°C for 16 – 21 
hours at 225 rpm. The ISRE luciferase reporter vector plasmid, renilla lucif-
erase vector plasmid and empty vector pcDNA were also transformed fol-
lowing the same protocol, but using 100 µg/ml ampicillin as the antibiotic.  
2.4 Plasmid isolation 
 
 PureYield™ Plasmid Maxiprep System (Promega) was used for iso-
lating plasmids according to the manufacturer’s protocol. The transformed 
E. coli cells were pelleted by centrifugation for 30 minutes at 5000 x g in 
room temperature. The supernatant was discarded and the pellet was re-
suspended in 12 ml of cell resuspension solution. Cell lysis solution (12 ml) 
was added to the tube and the solution was gently mixed 3-4 times followed 
by an incubation period of three minutes at room temperature. The neutrali-
zation solution (12 ml) was added and the tube was gently inverted 10 – 15 
times to mix the solution. The lysate was centrifuged at 7000 x g for 30 
minutes at room temperature. The lysate was filtered and added to the 
PureYield™ Plasmid Maxiprep column according to the manufacturer’s pro-
tocol. The concentrations of the purified plasmids were measured using 
Qubit 2.0 (Thermo Fisher Scientific). 
2.5 Cell line - Human Embryonic Kidney 293T (HEK293T)  
 
The HEK293T cells were grown in serum-containing cell culture me-
dium with 1% penicillin and 10% fetal bovine serum. The HEK293T cells 
were kept in an incubator at 37°C and with 5% CO2 for optimal conditions of 
growth.  
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2.6 Dual luciferase assay 
 
The HEK293T cells were transfected according to the Mirus Bio 
TransIT-LTI protocol using 24-well plates. The cells were plated 18-24 hours 
prior to the transfection with a 70-80% confluency. The seeding density of 
the cells was 0.05 x 106 and a cell confluency of 0.2 x 106   was maintained 
prior to the transfection. The previously prepared V and C protein plasmids 
at concentrations of 250 ng/ml, 500 ng/ml and 1000 ng/ml (final concentra-
tion) were used for all the experiments. For the transfection, ISRE-Luc re-
porter plasmid at a concentration of 200 ng/ml, renilla at 2 ng/ml and empty 
vector pcDNA at 1000 ng/ml were used. The same concentrations of ISRE-
Luc, renilla and pcDNA were used for each control. TransIT-LTI reagent and 
Opti-MEM reduced-serum medium were used as described in the Mirus Bio 
protocol (experimental setup shown in Appendix 2). A summary of the pro-
tocol is shown below.  
 
The Opti-MEM reduced-serum medium, plasmids, pcDNA, ISRE-Luc 
and renilla were added to the micro-centrifuge tube. After adding TransIT-
LTI reagent to the tube, it was incubated for 20 minutes at room temperature. 
The calculated amount of reagent and plasmid mixture was added to the 
wells of the 24-well plate in a drop-wise manner. The plates were incubated 
at 37°C for 18 – 24 hours. The next day, the Lipofectamine 3000 reagent was 
used for enhancing the transfection performance and reproducible results. 
The viral infection in HEK 263T cells was mimicked using poly(I:C) (1 g 
/ml). The poly(I:C) was added for only half of the wells of each concentration 
and the other half of the wells was used as controls. Poly(I:C) is a double-
stranded RNA molecule that is made synthetically, and mimics the molecular 
pattern associated with virus infections activating type I IFN responses via 
the melanoma differentiation-associated factor 5 (MDA-5) pathway (Démou-
lins et al., 2009). After 24 hours of incubation at 37°C, the growth medium 
was removed from the wells and cells were lysed using 100 µl of 1X passive 
lysis buffer (PLB). Then 10 µl of cell lysis solution from each well was added 
to a 96-well microplate for luminescence reading. Luciferase activity was 
measured by using an Infinity M1000 microplate reader (Tecan) according 
to the manufacturer’s protocol (Promega). The experiments were done twice 
with triplicates and all the values were normalised according to the control 
without poly(I:C). Relative luciferase expression was calculated as a per-
centage compared to the empty vector, pcDNA control. 
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3.1 Analysis of V and C genes and proteins of FmoPV, 
CDV and MeV 
 
The purpose of the multiple sequence alignment of V and C proteins 
is to identify the conserved amino acids region of FmoPV, CDV and MeV. 
All the V-specific domains of FmoPV, CDV and MeV contains a highly con-
served motif of seven cysteine residues (Figure 4). These unique conserved 
motifs are responsible for binding to zinc molecules. The amino acid lengths 
of the V proteins of CDV and MeV are the same, but the V protein of FmoPV 
is shorter than the others.  
 
Figure 4. Multiple sequence alignment of V proteins of FmoPV, CDV and MeV. The 
seven highly conserved cysteine residues are highlighted in purple. The other con-
served amino acids are also highlighted. The amino acid lengths of the V proteins 
of FmoPV; 276, CDV; 299 and MeV; 299.  
3 Results 
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The C proteins of FmoPV, CDV and MeV do not contain a highly conserved 
motif like V proteins. The C proteins of FmoPV, CDV and MeV are shorter 
in length and differ in amino acid sequence compared to the V proteins. 
 
 
Figure 5. Multiple sequence alignment of C proteins of FmoPV, CDV and MeV. The 
amino acid lengths of the C proteins of FmoPV, CDV and MeV are 170, 174 and 
186, respectively.  
3.2 Inhibition of luciferase expression by V and C proteins 
of FmoPV, CDV and MeV 
 
The relative immunomodulatory capabilities (inhibiting type I IFN sig-
naling) of the V and C proteins of FmoPV, CDV and MeV were measured 
according to the expression of ISRE responsive reporter gene on the plas-
mid using dual-luciferase assay. The normalised data shows the averages 
of two experiments. 
3.3 V proteins of CDV and MeV showed higher 
immunomodulatory capability than FmoPV  
 
Studies on the level of inhibition of ISRE reporter plasmid expression 
with different concentrations of V protein plasmids produced the following 
results. The level of inhibition by the V protein plasmid of FmoPV, CDV and 
MeV are calculated as a percentage, compared to the empty plasmid vector, 
pcDNA control (Figure 6). Expression of the V protein of FmoPV at a low 
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level (250 ng/ml plasmid for transfection) resulted in a reduced expression 
(59.71%) of the reporter gene.  Higher expression of the V protein gave a 
stronger inhibition of the reporter gene, with 42.59% relative luciferase ex-
pression when 500 ng/ml plasmid concentration was used for transfection 
and 39.83% relative luciferase expression with 1000 ng/ml of plasmid con-
centration.   
 
The V proteins of CDV and MeV had significantly higher inhibition 
than the V protein of FmoPV (Figure 6). The relative luciferase expression 
in the presence of CDV V protein was 13.38% (250 ng/ml), 8.95 % (500 
ng/ml) and 9.38% (1000 ng/ml). A similar high level of inhibition was ob-
served for V protein of MeV with relative luciferase expression of 17.06%, 
14.94% and 14.45% with respect to the given concentration of V protein 
plasmids. Interestingly, the V proteins of CDV and MeV were observed to 
have very similar concentration dependent inhibitory ability.  
 
 
Figure 6. A comparison of the ability of V proteins (FmoPV, MeV and CDV) to inhibit 
the type I IFN response induced by poly(I:C) stimulation. 
Figure 6 also presents a direct comparison of the inhibitory effect of 
the V proteins of FmoPV, CDV and MeV on type I IFN-induced expression. 
The V protein of CDV has a higher immunomodulatory capability than the 
other V proteins, leading to a reduction to 10% of the expression in the con-
trol. The V protein of FmoPV has the lowest inhibition of IFN pathway fol-
lowed by V protein of MeV.  
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3.4 The C proteins of FmoPV, CDV and MeV show very 
similar and reduced capability to inhibit the induced 
response to type I IFN  
 
The C proteins of FmoPV, MeV and CDV showed relatively similar 
but reduced type I IFN inhibition compared to the V proteins (Figure 7).  The 
relative luciferase expression induced by poly(I:C) was reduced in the pres-
ence of FmoPV C protein: 73.11% (250 ng/ml of plasmid used for transfec-
tion), 53.17% (500 ng/ml) and 42.33% (1000 ng/ml) compared to the control. 
These results indicated very clear concentration dependent inhibition by the 
C protein.  
 
 
Figure 7. A comparison of the ability of C proteins (FmoPV, CDV and MeV) to inhibit 
the type 1 IFN response induced by poly(I:C) stimulation. 
Interestingly, the results showed that the C proteins of CDV and MeV 
have very similar capability of inhibition as the C protein of FmoPV. For C 
proteins of CDV and MeV, the increasing plasmid concentration did not af-
fect inhibition of type I IFN induced expression (Figure 7). The relative lucif-
erase values for the C protein of CDV were 62.63%, 53.22% and 57.58% 
with respect to the different plasmid concentrations used for transfection. A 
similar result was obtained for the C protein of MeV with 49.43%, 46.89 and 
47.41% of relative luciferase expression for the different concentrations of 
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plasmids. These results suggest that the C proteins of CDV and MeV have 
a similar ability to inhibit the type I IFN pathway at different protein concen-
trations. The C protein of FmoPV shows a clear correlation between increas-
ing concentrations of plasmid for C protein expression and inhibition of type 
I IFN-induced expression.  
3.5 Comparison of type I IFN signalling inhibition by the V 
and C proteins 
 
The cumulative comparison of all the results for type I IFN signalling 
inhibition by the V and C proteins of FmoPV, CDV and MeV is shown in 
Figure 8. It is clear from this graph that V and C proteins of all the tested 
morbilliviruses have potent inhibition capability.  
 
 
Figure 8. A comparison of the ability of V and C proteins of FmoPV, CDV and MeV 
to inhibit type I IFN signalling induced by poly(I:C) stimulation. 
FmoPV - V FmoPV - C CDV - V CDV - C MeV - V MeV - C
pcDNA - 1000 ng/ml 100 100 100 100 100 100
Plasmid 250 ng/ml 59.71 73.11 13.38 62.63 17.06 49.43
Plasmid 500 ng/ml 42.59 53.17 8.95 53.22 14.94 46.89
Plasmid 1000 ng/ml 39.83 42.33 9.38 57.58 14.45 47.41
0
20
40
60
80
100
120
R
el
at
iv
e 
lu
ci
fe
ra
se
 e
x
p
re
ss
io
n
 (
%
)
Concentration of plasmids
25 
 
Morbilliviruses are highly infectious, mostly spread through direct 
contact and are responsible for severe and moderate distinct diseases (de 
Vries et al., 2015). According to previous studies all morbilliviruses initially 
target the immune system of the host, especially the type I IFN pathway, 
before spreading to the other cells of the body (de Vries et al., 2015). There-
fore, a better understanding of the immunomodulatory capabilities of these 
viruses is important for the control of these highly infectious viruses. As out-
lined in the introduction, the V and C proteins of morbilliviruses are respon-
sible for the down-regulation of type I IFN signalling at different levels. Stud-
ies have proven that the V and C proteins of these viruses are responsible 
for blocking different steps of this pathway (Pfeffermann et al., 2018). 
 
Previous studies related to the V and C proteins of the recently iden-
tified FmoPV have shown that it is structurally and pathogenically different 
from other morbilliviruses (Woo et al., 2012). This is the first study focusing 
on comparing the immunomodulatory capabilities of V and C proteins of the 
three morbilliviruses FmoPV, CDV and MeV. 
 
4.1 The V and C proteins of FmoPV, CDV and MeV reduce 
type I IFN induced gene transcription to different levels 
 
This study observed that the V and C proteins of FmoPV, CDV and 
MeV reduced the type I IFN induced gene transcription to different levels. 
Studies on the immunomodulatory effects of V and C proteins (Fontana et 
al., 2008; Sparrer et al., 2012; Chinnakannan et al., 2013) are available for 
MeV and CDV, but there is a lack of results for the V and C proteins of 
4 Discussion 
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FmoPV. The previous findings related to the ability of the V and C proteins 
of MeV and CDV to inhibit IFN-induced signalling are varying according to 
the virus isolate and cell type used in the experiments (Fontana et al., 2008). 
However, all the available results have shown that the V and C proteins of 
MeV and CDV inhibit type I IFN signalling. According to the study on the V 
and C proteins of MeV (Fontana et al., 2008), the V protein has a stronger 
inhibitory effect on signalling than the C protein. Furthermore, the studies of 
Sparrer et al. (2012) have shown that the C proteins of wild type and vaccine 
strains of MeV have different capability to inhibit type I IFN signalling. The V 
and C proteins of MeV used in this study were obtained from the isolate 97-
4588, which is a wild-type isolate found in the USA. However, Shaffer et al. 
(2003) and Ohno et al. (2004) have reported different observations for the 
inhibition ability of V and C proteins of wild-type and attenuated strains of 
MeV, due to differences in viral strains and cell types used.  
4.2 The V protein of FmoPV, CDV and MeV has stronger 
immunomodulatory capabilities than the C protein 
 
As outlined in the introduction, the V protein of morbilliviruses has 
higher immunomodulatory capabilities than C proteins. This study also 
shows the same observations for all the tested morbilliviruses. The V protein 
of CDV and MeV inhibited type I IFN signalling with greater efficiency than 
the C protein of the same morbilliviruses. In a previous study, a similar in-
hibitory ability of type I IFN signalling by the V protein of these morbilliviruses 
was reported (Chinnakannan et al., 2013). These findings were also similar 
to a previous study using recombinant knockout of the highly virulent CDV 
strain A75/17, where the V protein was shown to be the main antagonist 
player when it comes to inhibiting IFNα/β signalling and the C protein po-
tently inhibited the activation of the ISRE promoter (Röthlisberger et al., 
2010). 
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4.3 The specific immunomodulatory ability of the V protein 
of FmoPV 
 
The V and C proteins of FmoPV demonstrated different immunomod-
ulatory abilities compared to those of the other tested morbilliviruses. The V 
proteins of CDV and MeV strongly inhibited type I IFN signalling, while the 
V protein of FmoPV did not show similar inhibition. Interestingly, the C pro-
tein of FmoPV showed clear concentration-dependent inhibition of type I IFN 
signalling, while the C protein of the two other tested morbilliviruses gave 
similar reductions in response for all tested concentrations. Available litera-
ture has also shown similar dose-independent inhibitory effects for C pro-
teins of CDV and MeV (Chinnakannan et al., 2013;  Fontana et al., 2008).  
 
4.4 Pathological differences of V and C proteins of FmoPV, 
CDV and MeV  
 
The morbilliviruses used for analysis of V and C proteins belong 
to wild-type strains that cause severe infections. A previous study has 
shown that V and C proteins of wild type strains of morbilliviruses have 
higher capability to inhibit type I IFN signalling than attenuated strains (Sanz 
Bernardo et al., 2017).  Patterson et al. (2000) have shown, by using trans-
genic mice infected with MeV, that the V and C proteins of MeV act as viru-
lence factors and as a result, the mortality rate of mice infected with V gene 
defective MeV (V-) was significantly reduced compared to the mortality of 
mice infected with the Edmonston B vaccine strain of MeV (MV-Ed). The 
same study also showed that the spread of disease in mice infected by C 
gene defective MeV (C- MeV) was similar to MeV-Ed but with a lower motil-
ity rate. Another study illustrated how V proteins of wild-type MeV and CDV 
blocked type I IFN inhibition more effectively than the V proteins of the vac-
cine strain of MeV-Ed and the laboratory strain CDV-Ond (Chinnakannan et 
al., 2013). When the V and C proteins bind, the antiviral effect of the type I 
IFN response is reduced (Chinnakannan et al., 2013). Therefore, there is 
a significant relationship between pathology and inhibition of type I IFN re-
sponse by V and C proteins. We could assume that V proteins of CDV and 
MeV strongly inhibit type I IFN signalling, explaining that their spread is 
faster and virulence is higher than for FmoPV. Compared to the V protein, 
28 
 
the C protein of morbilliviruses showed reduced ability to inhibit type I IFN 
signalling indicating that those are not as pathogenically strong as the V 
proteins. 
4.5 Protein analysis and immunomodulatory capabilities of 
FmoPV, CDV and MeV  
 
The V-specific domain of FmoPV, CDV and MeV consists of highly 
conserved amino acids forming a motif that contains seven cysteine resi-
dues. As outlined in the introduction, these highly conserved amino acids 
are important for the abilities of V proteins of CDV and MeV to reduce the 
interferon response. The results obtained from this study also showed that 
the V protein of these morbilliviruses has stronger inhibitory abilities than the 
C protein. Further studies are required to compare these abilities with those 
of V and C protein of FmoPV.  
 
4.6  Limitations and future studies 
 
The study presented in this thesis is the first to compare the immuno-
modulatory capabilities of the concerned morbilliviruses. According to time 
and other constraints, the inhibition of ISRE promoter gene expression of 
the type I IFN pathway was the only focus of the experiments. Therefore, 
this study could be extended to test previously identified other inhibitory 
points of the pathway RIG-I/MDA-5, JAK1/TYK2, STAT1/STAT2 and IF-
NAR1/IFNAR2 and compare the inhibition by V and C proteins specifically. 
Also, the effects of mutations of V and C proteins of FmoPV on their ability 
to inhibit signalling can be further tested. This could be a possibility to check 
the immunomodulatory capabilities of vaccine and wild-type strains of mor-
billiviruses, especially of FmoPV.  
 
This experiment could also be complemented by investigating the 
protein concentrations and distributions using western blot (protein im-
munoblot) and in situ proximity ligation assay (PLA), respectively. Such in-
vestigations would be used to determine the expression of the V and C pro-
teins and to verify these results. These analyses were opted out from the 
current study due to time restrictions.    
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The immunomodulatory capabilities of the V and C proteins of 
FmoPV, CDV and MeV were examined in this study. The ability of V and C 
proteins of FmoPV, CDV and MeV in inhibiting type I IFN signalling was 
measured by the expression of an ISRE responsive reporter using a dual 
luciferase assay reporter system. The relative luciferase expression was 
used to analyse the immunomodulatory capabilities of each virus protein.   
 
The conclusion of this study is that the V and C proteins of FmoPV 
demonstrate a relatively low level of inhibition of type I IFN signalling com-
pared to the V and C proteins of CDV and MeV. The V protein of CDV 
showed the highest inhibition and the C protein of MeV. Further studies are, 
however, required to understand better the ability of V and C proteins to 
inhibit the type I IFN pathway, especially that of the V and C proteins of 
FmoPV.  
 
 
5 Concluding remarks 
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Appendix 1 – The details of V and C plasmid 
vectors  
 
Figure 1: Details of V and C plasmid vectors of FmoPV. As restriction sites, EcoRI 
at the 5’end and HindIII at the 3’ were used for both cDNAs 
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Figure 2: Details of V and C plasmid vectors of CDV. As restriction sites, EcoRI at 
the 5’end and HindIII at the 3’ were used for both cDNAs 
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Figure 3: Details of V and C plasmid vectors of MeV. As restriction sites, BamHI at 
the 5’end and EcoRI at the 3’ were used for both cDNAs 
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Figure 4: Vector map of pCMV-3Tag-1A 
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Appendix 2 – Experimental setup 
 
Transfection: 
 
Table 1: Experiment setup – Per well (containing 0.5 ml growth media with 
cells) according to the concentration of plasmids 
 
 
 pcDNA 
1000 ng/ml 
V or C plasmid 
250 ng/ml 
V or C plasmid 
500 ng/ml 
V or C plasmid 
1000 ng/ml 
 Plasmids &Reagents    Microliters   Microliters Microliters Microliters 
OPTI 50 50 50 50 
ISRE (200 ng/ml) 0.5 0.5 0.5 0.5 
Renilla (2 ng/ml) 0.5 0.5 0.5 0.5 
pcDNA (250 ng/ml) 2 1.5 1  
V or C Protein (250 ng/ml)   0.5 1 2 
Trans IT-LTI 1.8 1.8 1.8 1.8 
Total per well 54.8 54.8 54.8 54.8 
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